Interplay Between TGF-β Signaling and MicroRNA in Diabetic Cardiomyopathy

Cardiovasc Drugs Ther. 2023 Dec 20. doi: 10.1007/s10557-023-07532-2. Online ahead of print.

Abstract

In diabetic patients, concomitant cardiovascular disease is the main factor contributing to their morbidity and mortality. Diabetic cardiomyopathy (DCM) is a form of cardiovascular disease associated with diabetes that can result in heart failure. Transforming growth factor-β (TGF-β) isoforms play a crucial role in heart remodeling and repair and are elevated and activated in myocardial disorders. Alterations in certain microRNAs (miRNA) are closely related to diabetic cardiomyopathy. One or more miRNA molecules target the majority of TGF-β pathway components, and TGF-β directly or via SMADs controls miRNA synthesis. Based on these interactions, this review discusses potential cross-talk between TGF-β signaling and miRNA in DCM in order to investigate the creation of potential therapeutic targets.

Keywords: Diabetic cardiomyopathy; MicroRNA; TGF-β signaling pathway.

Publication types

  • Review